Immunotherapy Drugs Market Analysis
Immunotherapy Drugs Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune response. They are known as activation immunotherapies. However, some immunotherapies that suppress or reduce the immune response are known as suppression immunotherapies. Cell-based immunotherapies are useful for some types of cancers. Immune effector cells including macrophages, dendritic cells, lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells (NK Cell), etc., work collectively to protect the body against cancer by aiming at abnormal antigens articulated on the facade of the tumor cells. Therapies including granulocyte colony-stimulating factor (G-CSF), imiquimod, interferons as well as parts of cellular membrane from bacteria are approved for medical use. Some of the others such as IL-7, IL-2, IL-12, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans anda variety of chemokines are involved in preclinical and clinical studies.
An increase in the prevalence of cancer and a number of autoimmune diseases, the demand for immunotherapy drugs is likely to increase. The impact of these diseases can be ascertained from the fact that cancer caused 9.6 million deaths in 2018, as reported by the World Health Organization (WHO). The organization further stated that around 70% of deaths from cancer occur in low and middle-income countries. Moreover, with the rising need for mAbs, the immunotherapy drugs market is anticipated to have a positive outlook till the end of the forecast period 2019-2027. MAbs have a high affinity towards the specific disease cells as well as areas that require treatment. Accordingly, they can be utilized for therapies such as antibody-directed enzyme prodrug therapy and radio immunotherapy. The increased use of these antibodies in the drug development process is likely to boost the market’s revenue making capacity over the forecast period.
Another important factor driving the growth prospects of the global immunotherapy drugs market is the materialization of biosimilars. Dissimilar to generic drugs that have active pharmaceutical ingredients like original drugs, biosimilars are nearly identical to their creator biologic compounds. In view of the fact that biosimilars are less expensive than biologics therefore the sale of biosimilars among the patients and hospitals is likely to rise considerably during the forecast period. This is expected to augment the overall growth of the immunotherapy drugs market.
On the basis of therapy area, the cancer segment is likely to hold the maximum market share in 2018. The large share along with the high growth of this segment is due to the high predilection for immunotherapy as a first line of treatment in the management of cancer thereby leading to rising demand for the global immunotherapy drugs. On the basis of product type, the mAbs segment accounted for the maximum share of the market. The improvement of new drugs as well as the entry of new molecules such as zanolimumab, elotuzumab, onartuzumab, and obinutuzumab into the market will drive the growth of the global immunotherapy drugs market over the forecast period.
Increasing prevalence of cancer and rise in demand from the Asia Pacific region will drive the overall immunotherapy drugs market
According to National Cancer Institute, around 1,685,210 new cases of cancer are likely to be diagnosed in the U.S. in 2016 and about 595,690 people are estimated to die from the disease. Since immunotherapy is used as a first line of treatment in the management of cancer, the market immunotherapy drugs market will grow accordingly. North America is the largest region in the global immunotherapy drugs market and is expected to retain its dominance over the forecast period. Asia Pacific is likely to be the fastest-growing market over the forecast period. The elevated growth of this region can mainly be attributed to low cost of manufacturing of these drugs in the region, rising pricing and reimbursement scenario for immunotherapy drugs on the universal level and for major countries such as the Belgium, the U.K., France, Italy, Spain, Japan, China, and Australia. For instance, reimbursement scenario in the U.K. has impacted the cost of the drugs. Keytruda is an immunotherapy drug used for the treatment of melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial carcinoma, gastric cancer, and cervical cancer. Keytruda generally costs up to US$ 84,000 to the patients. To reduce the cost of this drug, the National Health Service (NHS) England, a publicly funded national healthcare system, and Merck & Co. Inc. entered into an agreement in June 2018, to reimburse the cost of this drug and provide it for routine use as per the National Institute for Health and Care Excellence (NICE) recommendations. NICE recommends NHS to provide reimbursements for this drug and make it affordable for the patients.
The market players in the immunotherapy drugs market are actively seeking collaborations and partnerships for the development of novel immunotherapy drugs. For instance, in April 2018, Bristol-Myers Squibb Company (BMS) and Illumina Inc. collaborated to utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of BMS oncology portfolio. The collaboration helped to develop a diagnostic version of Illumina’s TruSight Oncology 500 assay, including tumor mutation burden (TMB), and microsatellite instability for immunotherapies.
Similarly, in April 2018, Pfizer Inc. and Allogene Therapeutics Inc. entered into an asset contribution agreement to use Pfizer’s portfolio related to allogeneic CAR-T therapy, an investigational immune cell therapy, for cancer. This agreement acted as an attractive opportunity for Pfizer Inc. to continue the development of CAR-T therapy.
Some of the companies operating in the immunotherapy drugs market in the current scenario are GlaxoSmithKline, F. Hoffmann-La Roche AG, AbbVie, In., Merck & Co., Inc. Amgen, Inc., Bristol-Myers Squibb, Eli Lilly and Company, Novartis International AG, AstraZeneca plc and Johnson & Johnson.
Immunotherapy Drugs Market Taxonomy
On the basis of product type, the global market has been segmented as
On the basis of therapy area, the global market has been segmented as
On the basis of region, the global market has been segmented as